Drug Evaluation Committee Drug Development Utilizing Patients' Voices Patient Centricity by Pharmaceutical Companies
Clinical Evaluation Subcommittee
June 2018
The Clinical Evaluation Subcommittee has been working on the theme of "Patient Centricity" (drug development with the patient's voice) since fiscal year 2016, with the aim of advancing drug development together with patients. In the first year, with the aim of examining the necessity of Patient Centricity activities (hereafter referred to as "this activity") in drug development by pharmaceutical companies, we investigated the definition of this activity, regulatory authorities and public-private partnership organizations in Japan, the U.S., and Europe, and the current status of pharmaceutical companies. In FY2017, we continued to investigate specific cases by pharmaceutical companies, and analyzed the issues and effects found as a result. Furthermore, in collaboration with the JPMA Patient Cooperation Cooperation Committee, we actually confirmed the voices of patients and patient groups through interview surveys and compiled them into a report as the Subcommittee's data.
The ultimate goal of the task force is the implementation of drug development that utilizes the voices of patients in pharmaceutical companies. We hope that this report will be of help to pharmaceutical companies as they begin this activity in Japan.
Drug Development with the Patient's Voice - Patient Centricity by Pharmaceutical Companies- (3.4MB)